GoodRx to offer Sanofi’s Lantus insulin product at $35
ChandraDhas/iStock Unreleased via Getty Images

Healthcare savings platform GoodRx (NASDAQ:GDRX) announced a collaboration with Sanofi (NASDAQ:SNY) to offer the French drugmakerâs Lantus brand of insulin for U.S. patients with diabetes at $35 per month, regardless of their insurance status.
Accordingly, Americans can obtain a 30-day supply of Lantus for only $35 across 70,000 retail pharmacies that accept the GoodRx (GDRX) coupon, including CVS (CVS), Walgreens (WBA), and Walmart (WMT), effective today, the company said.

Early this year, Sanofi (SNY) agreed to lower the list price for Lantus and limit its out-of-pocket costs to $35 for patients with commercial insurance. The partnership builds on those plans, which take effect on Jan. 1, 2024, GoodRx (GDRX) added.
âSanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status,â GoodRxâs Chief Commercial Officer Dorothy Gemmell remarked.



More on Sanofi, GoodRx, etc.

GoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This In
GoodRx Stock: Earnings Momentum Keeps It Interesting
Sanofi: 3 Reasons For A Buy
Sanofi presents encouraging data on atopic dermatitis drug
Mirati Therapeutics soars on report of Sanofi takeover interest